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Protocol
AbstrAct
Introduction Within the context of antimicrobial 
stewardship programmes, de-escalation of antimicrobial 
therapy is one of the proposed strategies for reducing the 
unnecessary use of broad-spectrum antibiotics (BSA). The 
empirical treatment of nosocomial and some healthcare-
associated bloodstream infections (BSI) frequently 
includes a beta-lactam with antipseudomonal activity as 
monotherapy or in combination with other drugs, so there 
is a great opportunity to optimise the empirical therapy 
based on microbiological data. De-escalation is assumed 
as standard of care for experts in infectious diseases. 
However, it is less frequent than it would desirable.
Methods and analysis The SIMPLIFY trial is a 
multicentre, open-label, non-inferiority phase III 
randomised controlled clinical trial, designed as a 
pragmatic ‘real-practice’ trial. The aim of this trial is to 
demonstrate the non-inferiority of de-escalation from 
an empirical beta-lactam with antipseudomonal activity 
to a targeted narrow-spectrum antimicrobial in patients 
with BSI due to Enterobacteriaceae. The primary outcome 
is clinical cure, which will be assessed at the test of 
cure visit. It will be conducted at 19 Spanish public and 
university hospitals.
Ethics and dissemination Each participating centre has 
obtained the approval of the ethics review committee, 
the agreement of the directors of the institutions and 
authorisation from the Spanish Regulatory Agency (Agencia 
Española del Medicamento y Productos Sanitarios). 
Data will be presented at international conferences and 
published in peer-reviewed journals.
Discussion Strategies to reduce the use of BSA should be 
a priority. Most of the studies that support de-escalation 
are observational, retrospective and heterogeneous. A 
recent Cochrane review stated that well-designed clinical 
trials should be conducted to assess the safety and 
efficacy of de-escalation.
Trial registration number The European Union Clinical 
Trials Register: EudraCT number 2015-004219-19. Clinical  
trials. gov: NCT02795949. Protocol version: V.2.0, dated 16 
May 2016. All items from the WHO Trial Registration Data 
Set are included in the registry.
Background
The worldwide spread of antimicrobial resis-
tance is recognised as a current global public 
health threat. The implementation of steward-
ship programmes for optimising antibiotic use 
has been shown both to improve antibiotic use 
Strengths and limitations of this study
 ► It will be the first trial on de-escalation specifically in 
patients with bacteraemia due to Enterobacteriaceae.
 ► It will include patients independently of the source 
of bacteraemia or severity of clinical presentation.
 ► A remote automatic randomisation system and 
external evaluation by blinded investigators were 
used to avoid bias.
 ► It has been designed with daily clinical practice in 
mind.
 ► The open-label design is theoretically more prone 
to bias.
 ► Switching to oral therapy could potentially reduce 
the number of days in which patients are assigned 
to one or other arm.
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and also to help combat antimicrobial resistance.1 Stream-
lining or de-escalation of antimicrobial therapy is a strategy 
proposed to reduce the unnecessary use of broad-spectrum 
antimicrobials (BSA).1 2 This can be carried out by changing 
from combination therapy to monotherapy or by replacing 
the empirical antibiotic with one with a narrower spectrum 
of activity, irrespective of the microbiology results.1
Bloodstream infections (BSI) are known to be major 
causes of morbidity and mortality. They represent suit-
able organisms for carrying out a de-escalation strategy 
because they are very frequent, a high proportion of 
patients are treated with BSA and the susceptibility of 
the causative organisms is known. The Enterobacteriaceae 
as a group is the most common cause of community and 
nosocomial BSI, with a crude associated mortality of 
around 15%.3 The empirical treatment for nosocomial 
and some healthcare-associated BSI frequently includes 
a beta-lactam antibiotic with antipseudomonal activity 
in monotherapy or in combination. This imposes strong 
selection pressure, particularly on Pseudomonas aerugi-
nosa isolates, and may be selection of multidrug-resistant 
Enterobacteriaceae isolates. De-escalation according to 
microbiological results is assumed as standard of care 
by most infectologists; however, the reality is that de-es-
calation is much less frequent than is desirable.4 5 Some 
of the possible reasons for this phenomenon6–8 include 
the fact that the safety and efficacy of this treatment 
strategy are based only on a few observational studies9 10 
and expert recommendations.11 12 This was supported 
by a recent Cochrane review13 conducted among adults 
with sepsis, severe sepsis or septic shock, whose authors 
concluded that there is no adequate direct evidence that 
de-escalation of antimicrobial agents is effective and safe 
in this scenario. Randomised clinical trials of their safety 
and efficacy are needed, in order to establish ‘proof of 
concept’ and help make clinical decisions.
MeThods/design
study hypothesis
The aim of the trial is to demonstrate that de-escalation 
from empirical therapy with an antipseudomonal beta-
lactam to a targeted therapy is as effective and safe in 
patients with BSI due to Enterobacteriaceae as continuing 
with the empirical regimen.
design
The SIMPLIFY trial is a multicentre, open-label, phase III 
randomised controlled clinical trial, powered to demon-
strate the non-inferiority of de-escalation with respect 
to continuing with the antipseudomonal agent and 
designed as a real-world pragmatic trial. It was developed 
in accordance with an extension of the SPIRIT statement 
for reporting non-inferiority, superiority and equivalence 
trials.14 15
Participants and settings
The trial will be conducted at 19 public and tertiary 
Spanish hospitals with the support of the Spanish Network 
for Research in Infectious Diseases (REIPI) and the 
Spanish Clinical Research Network (SCReN). Thirteen of 
them are university hospitals. Patients will be evaluated 
for eligibility once Enterobacteriaceae is isolated from blood 
cultures and susceptibility data are available. Detection of 
eligible patients will be by daily review of blood culture 
results by infectious disease specialists from the bacter-
aemia team at each centre. To be enrolled, participants 
will need to fulfil all inclusion and exclusion criteria 
(box 1) and give written informed consent (the patient 
or a legally authorised representative).
randomisation
Stratified randomisation in a 1:1 ratio will be achieved 
using a centralised, web-based automated randomisa-
tion system integrated with the electronic case report 
form (eCRF) to manage assignment to the treatment 
arms. A copy of the randomisation list will be kept in a 
safe place in case technical problems arise. The only crite-
rion for stratification will be source of BSI (urinary tract 
vs any other) in order to ensure that the percentage of 
patients with urinary tract infections is similar in the two 
groups being compared. To guarantee an appropriate 
allocation concealment in an open trial, randomisation 
will not be stratified by site.
intervention
A decision tree of enrolment to the study is included in 
figure 1. As stated above, all included patients will already 
Box 1 Inclusion and exclusion criteria
Inclusion criteria
1. Written informed consent has been obtained from the patient or the 
legally authorised representative.
2. Age ≥18 years, not legally incapacitated.
3. Hospitalised patients with monomicrobial bacteraemia due to 
Enterobacteriaceae from any source.
4. The patient has received active empirical antibiotic therapy with an 
antipseudomonal beta-lactam (imipenem, meropenem, piperacillin-
tazobactam, cefepime, ceftazidime, aztreonam), alone or in 
combination with another antimicrobial agent, which started in the 
first 24 hours after the first positive blood culture was taken.
5. The isolate is susceptible to at least one of the antibiotics included 
in the experimental arm.
6. Intravenous antimicrobial treatment is planned for at least 5 days 
once Enterobacteriaceae is isolated from the blood culture.
Exclusion criteria
1. Life expectancy <30 days.
2. Pregnancy or nursing. For included women: failure to use a highly 
effective contraceptive method.
3. Isolation of carbapenemase-producing Enterobacteriaceae (because 
most hospitals do not use monotherapy in these cases).
4. Inclusion is delayed >48 hours after susceptibility data of the isolate 
are available.
5. Severe neutropenia (<500 cells/mm3) on the day of randomisation.
6. Planned duration of treatment  >28 days (eg, osteomyelitis, 
endocarditis).
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be receiving an antipseudomonal beta-lactam (mero-
penem, imipenem, piperacillin-tazobactam, cefepime, 
ceftazidime or aztreonam) before randomisation occurs. 
Patients will be allocated to one of the following treat-
ment arms:
Experimental group
The patient will change to an intravenous therapy with 
an active narrow-spectrum antibiotic according to 
the susceptibility results (EUCAST or CLSI criteria); 
the antibiotic will be chosen in the following order 
(the first active drug will be used): (1) ampicillin, 
2 g every 6 hours; (2) trimethoprim/sulfamethox-
azole, 160/800 mg every 8–12 hours; (3) cefuroxime, 
750–1500 mg every 8 hours; (4) cefotaxime 1–2 g 
every 8 hours or ceftriaxone, 1 g every 12–24 hours; (5) 
amoxicillin/clavulanate, 1 g/125 mg every 8 hours; (6) 
ciprofloxacin, 400 mg every 12 hours; and (7) ertapenem, 
1 g every 24 hours. Trimethoprim/sulfamethoxazole will 
only be used in urinary tract infections in the absence of 
an undrained renal abscess. Ciprofloxacin is included 
because, apart from being active against P. aeruginosa, it 
is not a beta-lactam.
Control group
Continuation of the antipseudomonal beta-lactam was 
being administered on an empirical basis: meropenem, 
1–2 g every 8 hours; imipenem, 0.5–1 g every 6 hours; 
piperacillin-tazobactam, 4/0.5 g every 6–8 hours; 
cefepime, 2 g every 8–12 hours; ceftazidime, 1–2 g 
every 8 hours; and aztreonam, 1–2 g every 8 hours.
Exceptions to the above rule
Third-generation cephalosporins should be avoided 
where there are inducible AmpC beta-lactamase-pro-
ducing Enterobacteriaceae (Enterobacter spp, Providencia 
spp, Morganella morganii, Serratia marcescens and Citrobacter 
freundii); hence, even if the isolates are strictly suscep-
tible, for patients in the control group, ceftazidime may 
be changed to any other antipseudomonal beta-lactam on 
the day of randomization. For patients allocated to the 
experimental arm, the options will be limited to trimetho-
prim/sulfamethoxazole, ciprofloxacin or ertapenem.
Extended-spectrum beta-lactamase (ESBL) producers 
could be included in the study based on attending 
physician’s criteria; in these cases, maximum doses of 
susceptible antibiotics are recommended.
Dose adjustment
Due to the nature of the study design as a real-world clin-
ical practice trial, antimicrobial dosage will be as deemed 
by the treating clinician, dependent on pharmacokinetic 
and pharmacodynamic (PK/PD) characteristics (such as 
higher doses for septic shock or high body mass). Dose 
adjustment will be made for all drugs as necessary in the 
case of renal or hepatic dysfunction, following summary 
of product characteristics recommendations.
Concomitant therapy
Even if the BSI is monomicrobial, the attending physi-
cian may consider the infection to be polymicrobial 
at source. If additional anaerobic or Gram-positive 
coverage is needed, concomitant use of oral metronida-
zole, clindamycin, vancomycin, teicoplanin, daptomycin 
or linezolid is allowed in both arms. Concomitant treat-
ment with any other systemic antibiotic with intrinsic 
activity against Gram-negative bacilli is not allowed. The 
administration of any of these drugs while the patient 
is receiving the study drug will be deemed a criterion 
for withdrawal. There are no absolute contraindica-
tions for the use of any other drug during the study. 
However, contraindications, warnings and precautions 
for use and possible interactions with study drugs are to 
be taken into account.
Duration of therapy
The appropriate duration of therapy is considered to 
be between 7 and 14 days, according to the attending 
physician’s criteria. Treatments lasting longer than 14 
days will be allowed only when there is an undrained 
Figure 1 SIMPLIFY—decision tree of patient enrolment.
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abscess present, in which case, a 4-week treatment is 
permitted.
Route of administration
Switching to oral therapy is allowed after the third 
day of therapy after randomisation if all the following 
conditions are fulfilled: clinical improvement has been 
achieved, absence of fever (>38°C), haemodynamic 
stability, adequate control of the source of BSI and 
absence of secondary foci, adequate oral intake, and 
no gastrointestinal conditions that might compromise 
drug absorption.
For patients in the experimental group, switching 
to oral therapy is allowed with the same intravenous 
drugs as follows: trimethoprim/sulfamethoxazole 
160/800 mg every 8–12 hours, cefuroxime axetil 500 mg 
every 8–12 hours, amoxicillin/clavulanate 875/125 mg 
every 8 hours or ciprofloxacin 500 mg every 12 hours. 
If the intravenous drug is ampicillin, amoxicillin 1 g 
every 8 hours will be used; if cefotaxime or ceftriaxone, 
then ceftibuten 400 mg every 12–24 hours or cefixime 
400 mg every 12–24 hours will be used; if ertapenem, this 
drug may be switched to the intramuscular route.
For patients in the control group, the preferred oral 
option is ciprofloxacin 500 mg every 12 hours for all 
patients. The protocol allows treatment with cefurox-
ime-axetil 500 mg every 8–12 hours or cefixime 400 mg 
every 12–24 hours only in cases of resistance to ciproflox-
acin; finally, parenteral ertapenem 1 g every 24 hours may 
be used for convenience if the isolate is resistant to all 
other oral options.
Rescue medication
No rescue medication is planned on behalf of the study 
if a patient has to withdraw from the trial for any reason; 
the attending physician will follow clinical guidelines for 
routine clinical practice and Good Clinical Practice rules.
Medication
As all the study drugs are recommended for BSI caused 
by Enterobacteriaceae, the sponsor will not provide the study 
drugs.16 Every site participating in the study is authorised 
to use the drugs through the normal provision of its 
hospital pharmacy.
schedule of visits
Patients included in the study will be followed for 60 days 
(±5 days) after diagnosis of the BSI (figure 2). Follow-up 
will be organised in seven planned visits at day 0 (baseline), 
day 1; days 3–5; days 7–14 (end of treatment); days 3–5 from 
end of treatment (test of cure, TOC); day 30±5; and day 
60±5. Visits at days 30 and 60 may be made by telephone.
The visit schedule is planned so as to obtain data on 
clinical status, sample collection, efficacy and safety 
variables, and adverse events. At the final evaluation at 
60 days, data on all outcome variables will be gathered. 
Additionally, data will be collected at unplanned visits, 
with special consideration given to the occurrence of any 
adverse event or recurrence.
outcomes
The primary outcome is clinical cure, which will be 
assessed at the TOC visit (3–5 days after the end of 
Figure 2 Schedule of visits and assessments. Except where otherwise specified, these refer to days from randomisation.
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antibiotic treatment). Death during treatment, change 
of antibiotic therapy due to clinical failure or need to 
prolong the treatment will be considered as failures 
(table 1). Secondary outcomes include early (5 days after 
end of treatment) and late (60 days) clinical and micro-
biological response, all-cause mortality (days 7, 14 and 
30), length of hospital stay, recurrence rates (relapse 
or reinfection) (day 60), safety of antibiotic treatment, 
including Clostridium difficile infections and number of 
antibiotic treatments with an antipseudomonal beta-
lactam; in a subgroup of patients, the rate of intestinal 
colonisation by P. aeruginosa resistant to carbapenemase 
or piperacillin/tazobactam, Stenotrophomonas spp, multi-
resistant A. baumannii and enterobacteria producing 
ESBL, carbapenemase and chromosomal AmpC (hyper-
production) or plasmid will be sought. Some of these 
secondary outcomes will be analysed as composite vari-
ables, following the Desirability of Outcome Ranking 
(DOOR)/Response Adjusted for Duration of Antibiotic 
Risk (RADAR) methodology. Outcome definitions, 
assessment and time frames for measurement are 
described in table 1. 
data collection, management and monitoring
The coordinating centre for this study is the Hospital 
Universitario Virgen Macarena, Seville, Spain, and the 
Clinical Trials Unit (CTU-Hospital Universitario Virgen 
del Rocío) has delegated sponsor functions on behalf 
of the Fundación Pública Andaluza para la Gestión de 
la Investigación en Salud de Sevilla (http://www. fisevi. 
com). Clinical research associates connected to the 
SCReN in public hospitals will carry out monitoring activ-
ities. Data collection will be conducted by trained staff at 
each participating centre and entered into a restricted 
access eCRF. These forms will be available at the eCRF 
web platform. Outstanding queries regarding the comple-
tion of the CRF will be sent to all participating centres as 
necessary to ensure accuracy of data.
Table 1 Outcome definitions and time frames
Primary endpoint and time frame Definition and assessment
Clinical cure
Days 3–5 after treatment*
TOC, the situation where all the following conditions are met: survival at the time 
of the evaluation; complete resolution of all symptoms and signs of infection (or 
return to the situation prior to current infection); no need for prolonged antibiotic 
treatment beyond the recommended duration* and no need for treatment 
modification due to unfavourable clinical response.
Secondary endpoint and time frame Definition and assessment
Clinical response
After 5 days of treatment (early response)
Until day 60 of follow-up (late response)
Same as clinical cure
Microbiological cure
After 5 days of treatment (early response)
Until day 60 of follow-up (late response)
Negative blood cultures and where applicable, negative cultures from samples 
taken from initial infection focus. ‘Presumptive microbiological cure’ is accepted 
in those cases where it is not possible to prove the negativisation of isolates 
from initial focus
All-cause mortality
7, 14 and 60 days of follow-up
Death for any reason
Length of hospital stay Time from randomisation to hospital discharge
Clinical recurrence (relapse or reinfection) 
rates
60 days of follow-up
Recurrence of at least one clinical and one analytical sepsis criterion, with 
presence or absence of bacteraemia
Microbiological recurrence (relapse or 
reinfection) rates
60 days of follow-up
New BSI episode with the same isolate as initial cultures with previously clinical 
and microbiological cure
Number of days of antipseudomonal beta-
lactam avoided
Until end of treatment
Number of days of antibiotic treatment with an antipseudomonal beta-lactam 
avoided
Ecological impact
7–14, 12–21, 30 days
Intestinal colonisation by multidrug-resistant Gram-negative bacilli
Safety of drugs—adverse events
Until day 60 of follow-up
Any untoward medical occurrence associated with the use of a drug in humans, 
whether considered drug related.
Composite secondary variables
7–14, 60 days of follow-up
Survival on day 14, number of days with an antipseudomonal beta-lactam 
avoided, presence or absence of side effects, including C. difficile infections, 
secondary MDRO infections and all drug-related adverse events
*7–14 days according to IDSA, except in the presence of undrained or late-draining abscesses, when up to 4 weeks are allowed.
MDRO, Multidrug resistant organisms.
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In order to avoid any association with personal data, all 
study samples will be anonymous and identifiable only 
by the patient’s alphanumeric study code. The objective 
and management of these samples are included in the 
patient’s information sheet and informed consent form.
The quality of all data collected will be carefully 
supervised by the CTU, and specific visits for source 
data verification are organised according to the moni-
toring plan. Furthermore, in order to minimise bias, 
at the interim analysis (when 50% of the sample has 
been included), an independent committee (three 
independent investigators from the REIPI) blinded to 
treatment assignment will review all accumulated data. 
This committee will advise the sponsor on the appropri-
ateness of continuing the clinical trial as designed.
isolates
All isolates will be sent to the central laboratory in the 
Hospital Universitario Virgen Macarena in Seville for 
susceptibility testing using reference methods and PCR 
characterisation and sequencing if necessary.
Eight selected hospitals will participate in the study of 
rectal carriage of ESBL-AmpC- and carbapenemase-pro-
ducing Enterobacteriaceae, by taking rectal swabs from 
participants at different times (as set out in the schedule 
of visits). To do this, samples will be taken by rectal swab 
from the patients of both treatment arms on the day of 
randomization, the day when treatment finish, the day of 
test of cure and visit of day 30. The presence of P. aeruginosa 
resistant to carbapenemase or piperacillin/tazobactam, 
Stenotrophomonas spp, multiresistant A. baumannii and 
enterobacteria producing ESBL, carbapenemase and 
chromosomal AmpC (hyperproduction) or plasmid will 
be sought. A written consent form for samples, approved 
by the ethics committees, is also provided for the study.
definition of analysis population and outcome measures
The following populations will be considered: the inten-
tion-to-treat population (ITTP) includes all randomised 
patients; the modified ITTP (mITTP) includes 
randomised patients who have received at least one dose 
of intravenous antibiotics; the clinically evaluable popu-
lation (CEP) includes patients who have completed 5 
days of the intravenous study drug or who die but have 
received at least one dose of intravenous antibiotics. The 
clinically and microbiologically evaluable population 
(CMEP) includes those in the CEP who have had micro-
biological tests (at least one blood culture 48 hours after 
randomisation).
The local principal investigator in the centre where 
the patient was included will assess the primary outcome 
(clinical cure) in the CEP at TOC. Due to the intrinsic 
characteristics of the primary outcome (soft outcome) 
and the study methodology (non-blinded), this evalua-
tion done will be reviewed later on the basis of clinical 
data recovered on two occasions by an external blinded 
investigator: first, during the interim analysis to monitor 
safety; second, before the complete cleaning and closure 
of the eCRF. For secondary endpoints, the CMEP will be 
eligible for early (day 5) and late (day 60) microbiological 
responses, the m-ITTP for all-cause mortality and length 
of hospital stay, and the CEP for the evaluation of recur-
rence rates and drug safety.
sample size
The sample size was calculated using Epidat V.4.0. Some 
of the data used to calculate it was derived from the study 
published by Retamar et al.17 Assuming estimated clinical 
cure rates of 85% in both groups, a non-inferiority margin 
of 10% difference between the two groups and treatment 
assignment in a 1:1 ratio, 344 patients in total (172 per 
study arm) are needed to achieve 80% power with a signif-
icance level of 5%. This allows for a 5% drop-out rate. 
The 10% non-inferiority margin was chosen as in recent 
trials of complicated urinary tract and intra-abdominal 
infections.18 19
statistical analysis
Absolute differences will be calculated with 95% CIs for 
the clinical cure rate between the two arms of the study 
at TOC. Multivariate analysis using logistic regression for 
the main outcome will be performed in order to ensure 
the independence of the treatment effect. Special consid-
eration will be given in the multivariate analysis to the 
centre of origin of the study sample. A Cox regression 
analysis of mortality until 60 days will be performed on 
the mITTP. For the superiority analysis, logistic regres-
sion will be used sequentially, using the methodology 
recently published by Evans et al20 for the composite 
variable (DOOR and RADAR analysis using survival at 
day 14, number of days of antipseudomonal beta-lactam 
treatment avoided, presence or absence of side effects, 
including C. difficile infections, secondary MDRO infec-
tions, and all drug-related adverse events). Antimicrobial 
doses are not fixed, and sensitivity analyses will therefore 
be applied to control potential bias.
Protocol violations
All protocol violations occurring after randomisation will 
be listed in the clinical study report, tabulated by subject 
and by recruitment centre.
eThics and disseMinaTion
Each of the participating centres has obtained the 
approval of an ethics review committee, the agreement of 
the directors of the institutions (who signed the contract 
of agreement with the sponsor of the study) and authori-
sation from the Spanish Regulatory Agency (Agencia 
Española del Medicamento y Productos Sanitarios). All 
the patients have to sign the informed consent previous 
to the randomisation (see online Supplementary data). 
Patients may withdraw from the study at any time without 
prejudice, as is documented and explained at the time of 
providing consent. The study will be carried out according 
to the principles of the Declaration of Helsinki and 
Directive 2001/20/EC of the European Parliament and 
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of the Council of 4 April 2001 on the harmonisation of 
the laws, regulations and administrative provisions of the 
member states relating to the implementation of Good 
Clinical Practice in the conduct of clinical trials on medic-
inal products for human use until the new Clinical Trials 
Regulation EU No 536/2014 becomes applicable, which 
will be no earlier than 28 May 2016. The confidentiality 
of records that might identify subjects in this study will 
be protected in accordance with EU Directive 2001/20/
EC. All laws for the control and protection of personal 
information will be carefully followed. The identities of 
patients will not be disclosed in the eCRF; names will 
be replaced by an alphanumeric code, and any material 
related to the trial, such as samples, will be identified in 
the same way, so that no personal information will be 
revealed.
Regarding to the dissemination plan, three commu-
nications with preliminary clinical data to national 
and international conferences (American Society for 
Microbiology/Infectious Diseases Society of America or 
European Congress of Clinical Microbiology and Infec-
tious Diseases) are proposed during the second year of 
the study. For the third year, a further presentation will 
be given at a national conference and two other presenta-
tions at international conferences with final or advanced 
data. Once we obtain the final results of the study, at least 
three publications are expected: one in a D1 journal and 
two in Q1 journals.
discussion
The extensive use of BSA and the dramatic increase 
in infections due to multidrug-resistant organisms are 
forcing the scientific community to look for strategies 
to combat this situation. In the real world, the applica-
tion of de-escalation to serious infections is less frequent 
than is desirable. The arguments against de-escalation 
include (1) the minimum inhibitory concentration of 
some narrow-spectrum drugs are closer to susceptibility 
breakpoints than carbapenems, for example, and some 
physicians may therefore feel safer using the latter; 
(2) subpopulations resistant to narrow-spectrum drugs 
may be selected and appear after some days of empir-
ical treatment, leading to treatment failure in case of 
de-escalation; (3) in the case of polymicrobial infec-
tions, it is not uncommon for only one of the pathogens 
to be isolated in blood cultures, so that simplifica-
tion of treatment may be less safe and effective than 
a broad-spectrum treatment; (4) there is some doubt 
about the real effectiveness of certain drugs against 
isolates producing specific mechanisms of resistance. 
Furthermore, although it is assumed that BSA has a 
greater impact on the selection of multidrug-resistant 
strains, some studies suggest that it may depend more 
on the duration of the treatment than the spectrum.16 
While none of these arguments have been proven, it is 
also true that there is no strong evidence for the safety 
of de-escalation strategies in these scenarios.
To the best of our knowledge, three randomised 
trials on de-escalation strategies, none of them specif-
ically focused on bacteraemia, have been published, 
which show significant differences from this study.21–23 
The one published by Falguera et al22 compared the 
efficacy of empirical versus targeted treatment on the 
basis of urine antigen results in hospitalised patients 
with community-acquired pneumonia. The article 
published by Kim et al23 evaluated the efficacy of early 
use of imipenem/cilastatin and vancomycin followed 
by de-escalation versus conventional antimicrobials 
without de-escalation for patients with hospital-ac-
quired pneumonia in intensive care units (ICUs). The 
last one, published recently by Leone et al,24 included a 
limited number (n=116) of ICU-admitted patients with 
severe sepsis; its primary outcome was duration of ICU 
stay and not effectiveness of both treatment strategies. 
In that study, de-escalation followed the recommenda-
tions of guidelines, not a prespecified protocol based 
on the clinical impact of the antibiotics. There was no 
significant difference in mortality, although unexpect-
edly, patients in the experimental arm had a higher rate 
of superinfections (27% vs 11%; p=0.03). These results 
contrast with a recent systematic review and meta-anal-
ysis that included 25 studies with data on de-escalation 
based on culture results, which showed a significant 
reduction in the relative risk (RR) of death (RR 0.44, 
95% CI 0.30 to 0.66; p<0.0001). It is important to note 
that many of the included studies in the meta-analysis 
were observational, were retrospective and had a high 
degree of heterogeneity.25
Several authors have warned about the considerable 
inconsistencies in definitions of de-escalation. In 2015, 
Weiss et al26 elaborated a consensual definition of de-es-
calation that allowed beta-lactams to be ranked according 
to both their spectra and their ecological impact. The 
authors underlined the difficulty of reaching consensus 
on the relative ecological impact of each individual drug. 
In 2014, Madaras-Kelly et al27 used the Delphi approach 
to develop an antibiotic spectrum score to measure de-es-
calation. We shall therefore include both concepts in our 
analysis, using Outcome Ranking (DOOR) and Response 
Adjusted for Duration of Antibiotic Risk (RADAR) anal-
yses.20
Switching from intravenous to oral therapy as soon 
as the patient is clinically stable can reduce the risk of 
adverse events related to intravenous therapy, length of 
hospitalisation and cost. It can be applied regardless of 
the source of infection and underlying conditions when-
ever a good option that achieves the PK/PD targets is 
available.28 In our study, switching to oral therapy is 
allowed in both arms to avoid exposing patients in the 
control arm to unnecessary risks.
The SIMPLIFY trial has several strengths. In the first 
place, it will be the first trial on de-escalation specifically 
in patients with bacteraemia due to Enterobacteriaceae. 
Second, it will include patients independently of the 
source of bacteraemia or severity of clinical presentation. 
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Third, it was designed with daily clinical practice in mind. 
We hope that, if there is reasonable evidence to reject the 
null hypothesis, it will encourage implementation of this 
type of strategy in daily practice.
Trial sTaTus
 ► Funding for the study was approved on 
15 August 2015 and available for study expenses in 1 
January 2016.
 ► Ethics committee approval for the 19 sites included 
was obtained on 15 March 2016.
 ► Authorisation from the Spanish Regulatory Authority 
was obtained on 18 March 2016.
 ► The study has been approved for a recruitment 
period of 2 years.
 ► Dissemination of results directed to patients will be 
channelled through the Spanish Clinical Studies 
Registry (Agencia Española del Medicamento y 
Productos Sanitarios), whose content is adapted to 
patients.
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